Abstract
Introduction
In mid-2016, a commentary was published in INNOVATIONS in Pharmacy reviewing, from the perspective of the standards of normal science, modeled technology assessment claims published in Value in Health from January 2015 to December 20151. This systematic review concluded that of the 16 identified papers, 14 presented a cost-per-QALY analysis, with 9 presenting their claims in a lifetime cost-per-QALY framework. The technology assessments presented, while conforming to ISPOR recommended standards, failed to meet the standards of normal science: the claims were neither credible, nor were they evaluable and replicable. They were best seen as imaginary claims created by imaginary modeled worlds. Recipients of these claims had no idea whether they were right or whether they were wrong, and they would never know as the claims were immune to failure. Reviews of modeled studies published in Pharmacoeconomics and the Journal of Medical Economics over the same time period came to the same conclusion 2 3. These reviews of cost-effectiveness models are part of a series of commentaries published in INNOVATIONS in Pharmacy over the last 12 months that have focused on the evidentiary standards for claims assessment. These standards are required or recommended by technology assessment agencies such as the National Institute for Health and Care Excellence (NICE) in the UK and the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, professional groups such as the International Society for Pharmacoeconomics and Outcomes research (ISPOR) and the Academy of Managed Care Pharmacy (AMCP) in the US and independent research groups such as the Institute for Clinical and Economic Review (ICER) 4 5 6 7 8 9 10. The common theme in these commentaries has been that the standards proposed and accepted in health technology assessment in the construction of non-evaluable modeled claims for pharmaceutical products and devices should be seen as pseudoscience (a.k.a. pure bunk); as intelligent design rather than natural selection 11 12 In case this characterization might appear as an unnecessarily harsh judgement on standards that have been in place for 30 years or more and which have been applied in literally thousands of published, peer review studies and evaluations by technology assessment groups, the commentaries recently pointed to the latest version of the guidelines released in March 2017 by the Canadian Agency for Drugs and Technologies in Health (CADTH). The CADTH guidelines made it quite clear that their technology assessment framework is not to be judged by the standards of normal science 13 . The guidelines are designed to set criteria for the construction of imaginary simulations to support cost-outcomes claims, to 'inform' health system decision makers, not to test hypotheses. Supporting claims that are credible, evaluable and replicable are put to one side by CADTH in favor of the construction of imaginary worlds. Typically an imaginary simulation of benefits and harms, focused on health related quality of life (HRQoL) over the lifetime of a hypothetical target population.
The purpose of this second review of health technology assessment studies published in Value in Health is to consider whether the standards of normal science continue to be put to one side, with the Journal continuing to accept simulated nonevaluable claims generated by imaginary worlds. The period covers January 2016 to December 2016. It will be followed by reviews over the same time period for Pharmacoeconomics and the Journal of Medical Economics.
Methods
A systematic review, following the PRISMA-P checklist (MeSH terms 'cost', 'cost effectiveness', 'Markov', 'QALY') of all papers published in Value in Health in 2016 was undertaken 14. In order to judge whether the modeled claims presented met the standards of normal science four questions were considered:
• Is the model capable of generating testable claims?
• Did the author(s) attempt to generate testable claims? • Did the authors suggest how the claims might be evaluated? • Did the author(s) caution readers as to the implications of generating non-testable claims?
Each author independently reviewed the selected studies with consensus agreement reached on the assessment.
A testable claim was defined as one that could be evaluated empirically in a timeframe relevant to the needs of a formulary committee (ideally a period of 2 to 3 years). This period was chosen because a testable claim was seen as provisional. A product or device could, in this context, be accepted by a formulary committee for formulary listing, but subject to an agreement with the manufacturer to report back to the committee with evidence to support the claims made. These claims could be for anticipated product comparative effectiveness, for the impact of the product on resource utilization or some combination of these to support a claim for incremental cost-effectiveness. (Table 1) . As well, three systematic reviews were identified as these were directly related to the issues raised in this review ( Table 2 ).
• None of the claims presented in other 12 papers were credible, evaluable and replicable • Modeled time horizons for the claims presented in these 12 papers ensured the claims were immune to failure • Five of these economic evaluations were funded directly by pharmaceutical manufacturers and all simulated claims that supported the manufacturer's product
• Two more of the economic evaluations had manufacturer links and both supported the manufacturer's product 19 27 • None of the papers considered how the claims might be evaluated in treatment practice
Modeled Claims and Systematic Reviews
In terms of the questions raised, none of the reviews addressed the issue of the credibility, evaluation and replication of modeled claims neither did they explicitly recommend or caution against accepting the modeled claims as the basis for formulary submissions. The only qualification here is from the Brilleman et al study which, in addressing claims for cost-effectiveness modeled on clinical trials, points to the lack of standards potentially impacting model-based claims for cost-effectiveness and the need for reporting on cost-allocation 28 . A key point to note in the Brilleman et al study is that: 'None of the articles included in our review used statistical methods to adjust for non-adherence or incorporate non-adherence information directly into the economic evaluation' (p. 103).
Discussion
As noted above, the common theme in the commentaries published in INNOVATIONS in Pharmacy since mid-2016 is that the recommended standards and their application in health technology assessments fail to meet the standards of normal science 4 . Rather than focusing on generating testable hypotheses to assess anticipated comparative product performance, the studies fall back on creating modeled imaginary worlds in which the comparative claims are immune to failure. The exemplars here are the lifetime cost-per-QALY willingness-to-pay 'reference case' model structures, which support 'information only' formulary submissions where the claims are non-evaluable 6 . This review of economic evaluations in Value in Health for calendar 2016 demonstrates that, despite criticisms raised against the construction of simulated imaginary worlds and their characterization as 'pseudoscience', this acceptance of imaginary constructs continues.
Consider the question, for example, of cost-per-QALY estimates and willingness-to-pay thresholds. Imaginary model simulations that yield lifetime claims that propose that market entry prices of a product are not cost-effective are, as noted in reviews of ICER evidence reports, immune to failure 8 9 10 . As such they fail the standards of normal science and should be rejected.
Modeled Claims
Once a study design commits to a long-term or lifetime Markov (or similar) model, there is no chance that the evaluation will generate claims that are credible and evaluable. Irrespective of the technical appeal in constructing multi-health state treatment pathway models that may extend for decades into an unknown future, with assumptions justified to appeals to literature or short term RCTs, the reader has to take the claims at face value. The Gregory et al paper, to give one example, projects on a yearly cycle from age 10 years to death or 100 years in the risks from computed tomography in Ireland 15 Other models in Value in Health have lifetime horizons, horizons of 25 years and horizons of 20 years.
Certainly, if we are prepared to suspend our disbelief in these constructs, we could point to a number of ways in which the 'realism' of the imaginary world could be enhanced. These have been detailed in previous commentaries and could include assumptions capturing anticipated patterns of persistence and adherence, presence and impact of comorbidities, anticipated pricing policies for annualized whole sale acquisition cost (WAC) price increases, possible WAC discounting to target patient groups, entry of pipeline competitor products and assumptions as to unknown but possibly defensible therapy switching patterns following initial response. Unfortunately, 'improving' the appeal of an imaginary construct merely increases the number of competing scenarios. Rather than providing 'more information' to support decision making, the more likely result is information overload and the rejection of the model. Consider, for example the issues of adherence and persistence. These are typically overlooked (or ignored) in constructing lifetime models. This is an odd decision given that there is now ample evidence for limited persistence with the majority of patients in disease areas abandoning a therapy within two to three years of an index prescription. If claims for persistence (let alone adherence) are based upon RCTs then as Brilleman et al point out, the evidence base may be somewhat questionable 28 .
The belief in the credibility of modeled claims may be further tested by manufacturer sponsored models, which readers might regard as 'marketing exercises'. In this review, five of the economic evaluations were sponsored or funded by manufacturers. As noted, all of these supported non-evaluable claims for the manufacturer's product. The absence of an evaluable claims means that there is no basis for assessing the 'validity' of the model claims. Competing models sponsored by manufacturers in the same class of comparator products might, not surprisingly, come to quite different conclusions. If journals such as Value in Health are prepared to publish manufacturer support models the, at least, there could be a 'red flag' annotation with the peer review process assessing (and reporting) on the model presented in the context of other models in the therapy area. EEven so, we will still have competing claims where the authors of the systematic review will attempt to explain that variation in terms of model structures, assumptions and presumptions of willingness-topay; an exercise which is pointless in the absence of modeled credible and evaluable claims with possible feedback from target populations.
Systematic Reviews
Even if the authors of imaginary worlds claim to be adherent to a 'reference case' mandated by a technology assessment group, there is ample opportunity to propose alternative model structures and input assumptions to make the case for comparative efficacy or effectiveness. It might be argued that subjecting a submitted model to the ministrations of an evidence review group would resolve this issue. Unfortunately, it does not solve the problem. Blinded assessments by competing review groups could come to quite different conclusions as to the 'preferred' model structure and the 'appropriate' input assumptions.
The Kirsch review of Markov modeling in disease management programs, following the ISPOR good practice guidelines for decision-analytic modeling, reviewed 16 studies 30 . In chronic heart disease the results ranged from cost savings of $657 and an increase of 0.0051 QALYs to an increase in costs of $4,607 per life year gained (LYG) and $146,544 per QALY. The two asthma studies also yielded cost savings or additional costs, with the five diabetes studies reported again both cost savings and additional costs. A detailed comparison of the various models was presented pointing to varying quality ('far from perfect') and coverage in terms of, for example, model structure, model cycle length, time horizon, utility weights, costs and parameter sensitivity. The author found it difficult to determine whether funders tried to influence study results or prevent the publication of unfavorable results.
Kirsch concluded that if the problems identified in the review are addressed then 'Markov models should be more suitable to evaluate economic effects of multicomponent interventions, and provide helpful information for decision makers' (p. 1052) 30 . Apart from the question of what is considered 'helpful' as opposed to possibly misleading information, this conclusion misses the point. At no stage in the review is the issue of establishing credible, evaluable and replicable claims for disease management programs considered. Even if model builders 'improved' the quality of the Markov model decision makers would be no further ahead. They would still be faced with imaginary claims and the possibility of an endless procession of diverse claims. We are still in the CADTH-mandated realm of pseudoscience, hoping that our non-evaluable claims will 'inform' decision makers.
The same objections apply to the Nunes et al review of longterm mechanical circulatory support 29 . Following a literature search a total of 11 country-specific cost-effectiveness analyses were identified. Once again the object is seen to be to 'inform' decision makers 'such that societal benefit is maximized'. The focus is on non-evaluable ICER thresholds rather than on presenting claims for devices that are credible, evaluable and replicable. The non-evaluable modeled results, not unexpectedly, vary widely. In mechanical circulatory support as a bridge to transplantation. ICERs between this support and medical management ranged from C$85,025 and C$200,166 per QALY and for destination between C$87,622 and C$1,257,946 per QALY. The authors concluded that the adoption of mechanical circulatory support has occurred despite, apparently, not achieving stated or implied costeffectiveness thresholds. Indeed, no study in the review 'concluded that mechanical circulatory support is costeffective with respect to optimal medical management'. While an assessment of possible contributing factors is apparently outside the scope of the review, one possible reason is that decision makers are not interested in being merely 'informed' through imaginary ICER models, presenting with such diverse claims, but are looking to evaluable claims and feedback from those claims to support purchasing decisions.
A major criticism of modeled claims for cost-effectiveness is that the models typically ignore issues of adherence and persistence with therapy. In previous commentaries it has been pointed out that if patients are non-persistent with therapy then if the majority of patients are non-compliance within two to three years of an index prescription 4 . It makes little sense to advocate formulary acceptance from a lifetime high-compliance cost-utility model. The importance of the Brilleman et al review is to emphasize how poorly adherence and persistence behavior are captured in clinical trial protocols and the importance of this for economic evaluations alongside clinical trials 28 . To which might be added the implications of taking trial end points as inputs to the creation of modeled imaginary worlds when these are potentially impacted by compliance behavior.
Conclusions
In a recent commentary on the ICER evidence review for PCSK9 inhibitors, the question was raised as to the likelihood that authors of health technology assessments could put what can be seen as the pointless construction of evidence and comparative claims from imaginary worlds behind them 10 .
Committing themselves instead to a research program for comparative claims assessment that embraced the standards of normal science and not its explicit rejection as evidenced by the latest CADTH guidelines 13 . In support of this, it was also proposed that journal editors could make it clear to their readership that published modeled claims, if they persisted in focusing on non-evaluable claims, could caution that the results presented did not meet the standards of normal science. A 'red flag' warning that would clarify circumstances where the modeled claims could be interpreted as a marketing exercise.
The PCSK9 commentary concluded that this 'reformation' was unlikely to occur 10 . There were too many vested interests in supporting the status quo. After all, with over 30 years acceptance and publication of literally thousands of nonevaluable claims in the leading journals, and acceptance of this commitment to constructed evidence by agencies such as NICE, CADTH and the PBAC, the discomfiture would be (to say the least) embarrassing. Let alone, it should be added, the impact on thousands of graduate students and others who have been trained to construct imaginary worlds and put the standards of normal science to one side. Richard Dawkins, in Unweaving the Rainbow, recognizes our willingness to feed on 'superstition, the paranormal and astrology' 31 . Or, as he describes it, our continuing appetite for being 'Hoodwink'd with faery fancy' . Perhaps we could recognize our appetite for 'faery fancy' and put the endorsement and publication of modeled imaginary worlds behind us. Markov model with a base-case time horizon of 20 years (considered equivalent to lifetime). Assessed the cost-effectiveness of six alternative first-line treatments, to include anti-CD20 monoclonoal antibody obinutuzumab plus chlorambucil (GClbHoffman La Roche) in untreated patients with chronic lymphocytic leukemia unsuited for fulldose fludarabine therapy from a UK NHS perspective. Three health states: progression free survival, progression and death. In basecase GClb cost-effective against all comparators in the model under a range of plausible modeled scenarios.
Claims presented are non-evaluable No recommendation for protocols to support claims assessment to meet required standards of normal science.
Bijlani et al20
Prostate surgery costs with roboticassisted versus retropubic radical prostatectomy
Intuitive Surgical
Modeled care pathway analysis, including multiple iterations with pathways, from hospital and payer perspectives comparing robotioc assisted laparoscopic prostatectomy (RALP -the sponsor's product) versus retropubic radical prostatectomy (RRP). Clinical outcomes modeled from systematic literature review. Monte-Carlo probabilistic sensitivity analysis generated claim that RALP had a 38% to 99% probability of cost-savings. A partitioned lifetime survival model with three disease states (preprogression, postprogression and death) extrapolating beyond the 5-year end point of the ICON7 trial for bevacizumab in advanced ovarian cancer. The study followed on the NICE decision not to recommend bevacizumab (a Roche product) for advanced ovarian cancer which was not based on the unlicensed lower dosage of the drug despite being used in the NHS and the ICON7 trial. The analysis, given NICE willingness-to-pay thresholds, was to consider if the lower dose was cost effective versus chemotherapy alone. The base-case analysis demonstrated that in none of the scenarios was bevacizumab cost-effective at the NICE conventional willingness-to-pay thresholds. Price reductions of 46% and 67% would be required to meet NICE thresholds. In a longterm scenario price reductions would be 21% and 45%. 
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